Moody's Investors Service ("Moody's") assigned an A2 rating to the new senior unsecured notes issuance of Bristol-Myers Squibb Company ("Bristol"). There are no changes to Bristol's existing ratings including the A2 senior unsecured ratings and the outlook remains unchanged at negative. Proceeds o...
Moody's Investors Service ("Moody's") confirmed the ratings of Bristol-Myers Squibb Company ("Bristol"). The ratings confirmed include the A2 ratings on senior unsecured bonds and a senior unsecured revolving credit facility, the (P)A2 senior unsecured shelf rating, the (P)A3 subordinated shelf rati...
A director at Bristol Myers Squibb Co bought 8,500 shares at 49.810USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Moody's Investors Service ("Moody's") assigned an A2 ratings to the new senior unsecured notes offering of Bristol-Myers Squibb Company ("Bristol"). There are no changes to Bristol's existing ratings including the A2 senior unsecured long-term ratings or the Prime-1 short-term ratings. The outlook r...
Moody's Investors Service commented that Bristol-Myers Squibb Company's (A2 stable) announcement that it will acquire Mirati Therapeutics, Inc. is credit negative. The deal enhances Bristol's oncology product portfolio and pipeline opportunities, but carries commercial and R&D execution risk given M...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.